The most important AI company you've never heard of

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

Charles Mather, IV Biography and Net Worth

Director of Eyenovia

Mr. Mather has been a member of our Board of Directors since March 2018. Since October 2019, Mr. Mather has been Managing Director, Equity Capital Markets at Suntrust Robinson Humphrey, Inc. Prior to that, since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015, he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co- Head of the Private Equity Group. Mr. Mather serves on the board Wentz LLC. Mr. Mather also served on the board of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) until February 2019 and The Finance Company of Pennsylvania until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

What is Charles E. Mather, IV's net worth?: The estimated net worth of Charles E. Mather, IV is at least $58,150.25 as of May 26th, 2023. Mr. Mather, IV owns 77,544 shares of Eyenovia stock worth more than $58,150 as of May 20th. This net worth evaluation does not reflect any other assets that Mr. Mather, IV may own. Learn More about Charles E. Mather, IV's net worth.
How do I contact Charles E. Mather, IV?: The corporate mailing address for Mr. Mather, IV and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Charles E. Mather, IV's contact information.
Has Charles E. Mather, IV been buying or selling shares of Eyenovia?: Charles E. Mather, IV has not been actively trading shares of Eyenovia in the last ninety days. Most recently, on Friday, May 26th, Charles E. Iv Mather bought 3,000 shares of Eyenovia stock. The stock was acquired at an average cost of $2.49 per share, with a total value of $7,470.00. Following the completion of the transaction, the director now directly owns 77,544 shares of the company's stock, valued at $193,084.56. Learn More on Charles E. Mather, IV's trading history.
Who are Eyenovia's active insiders?: Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.
Are insiders buying or selling shares of Eyenovia?: In the last twelve months, Eyenovia insiders bought shares 13 times. They purchased a total of 323,711 shares worth more than $566,174.16. The most recent insider tranaction occured on March, 28th when Major Shareholder Stuart M Grant bought 100,000 shares worth more than $98,000.00. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.
Information on this page was last updated on 3/28/2024.

Charles E. Mather, IV Insider Trading History at Eyenovia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2023	Buy	3,000	$2.49	$7,470.00	77,544
5/18/2022	Buy	7,000	$2.03	$14,210.00	48,322
3/31/2022	Buy	4,000	$3.12	$12,480.00
11/1/2021	Buy	4,000	$3.83	$15,320.00
5/28/2021	Buy	3,000	$4.76	$14,280.00	26,359
9/19/2018	Buy	4,000	$4.79	$19,160.00

Charles E. Mather, IV Buying and Selling Activity at Eyenovia

Eyenovia Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $0.75

$0.75

$0.87

50 Day Range

MA: $0.91

$0.52

$1.70

2 Week Range

Now: $0.75

$0.50

$3.59

Volume

1,021,500 shs

Average Volume

1,109,261 shs

Market Capitalization

$40.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Elon’s New Device is About to Shock the World

From InvestorPlace | Ad

Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.”

Click here to see the details because there’s a lot of money at stake.